HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.

AbstractBACKGROUND:
Iron supplementation for hypoferremic anemia could potentiate bacterial growth in the cystic fibrosis (CF) lung, but clinical trials testing this hypothesis are lacking.
METHODS:
Twenty-two adults with CF and hypoferremic anemia participated in a randomized, double-blind, placebo-controlled, crossover trial of ferrous sulfate 325mg daily for 6weeks. Iron-related hematologic parameters, anthropometric data, sputum iron, Akron Pulmonary Exacerbation Score (PES), and the sputum microbiome were serially assessed. Fixed-effect models were used to describe how ferrous sulfate affected these variables.
RESULTS:
Ferrous sulfate increased serum iron by 22.3% and transferrin saturation (TSAT) by 26.8% from baseline (p<0.05) but did not affect hemoglobin, sputum iron, Akron PES, and the sputum microbiome.
CONCLUSIONS:
Low-dose ferrous sulfate improved hypoferremia without correcting anemia after 6weeks. We did not observe significant effects on sputum iron, Akron PES, and the sputum microbiome. Although we did not identify untoward health effects of iron supplementation, a larger blinded randomized controlled trial would be needed to fully demonstrate safety.
AuthorsAlex H Gifford, Diana M Alexandru, Zhigang Li, Dana B Dorman, Lisa A Moulton, Katherine E Price, Thomas H Hampton, Mitchell L Sogin, Jonathan B Zuckerman, H Worth Parker, Bruce A Stanton, George A O'Toole
JournalJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (J Cyst Fibros) Vol. 13 Issue 3 Pg. 311-8 (May 2014) ISSN: 1873-5010 [Electronic] Netherlands
PMID24332997 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Ferrous Compounds
  • Hepcidins
  • Placebos
  • hepcidin 25, human
  • ferrous sulfate
Topics
  • Adolescent
  • Adult
  • Anemia, Iron-Deficiency (drug therapy, etiology, metabolism)
  • Cross-Over Studies
  • Cystic Fibrosis (complications, metabolism)
  • Double-Blind Method
  • Female
  • Ferrous Compounds (administration & dosage, adverse effects)
  • Hepcidins (metabolism)
  • Humans
  • Male
  • Microbiota (drug effects)
  • Middle Aged
  • Placebos
  • Sputum (drug effects, microbiology)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: